流感创新药新星征祥医药（南京）集团股份有限公司近期正式向港交所主板递交上市申请，试图通过资 本市场募资破解发展困局。其核心产品为2025年7月获国家药监局批准上市的新型抗流感药"玛硒洛沙韦 片"（商品名：济可舒），也是公司冲击IPO的核心底气。 "玛硒洛沙韦片"为我国自主研发、拥有全球自主知识产权的新一代靶向流感病毒RNA聚合酶PA抑制 剂，亦是2025年国家药监局批准上市的4款国产抗流感新药之一，定价与罗氏的玛巴洛沙韦一致为222 元/盒，是目前最贵的国产流感创新药。 有投资者注意到，受招股书披露时间节点限制，玛硒洛沙韦片获批后实际销售表现并未纳入此次披露的 文件中。这意味着，投资者无法通过招股书准确判断这款核心产品的真实市场竞争力与商业化潜力。 与此同时，征祥医药的资金状况已捉襟见肘。2024年以来持续亏损，截至2025年9月30日，公司负债总 额高达12.6亿元，资产负债率达415.84%，远超生物医药行业合理区间。核心产品业绩未显、财务压力 濒临红线，征祥医药仓促递表后的上市之路布满荆棘。 核心产品销售缺位 征祥医药独家商业化产品玛硒洛沙韦片，作为被寄予厚望的创新产品，其市场表现尚未能为公司IPO提 ...

Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]

Group 1 - Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as its sole sponsor [1] - Zhengxiang Pharmaceutical is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies to address unmet medical needs in the fields of viral infectious diseases, oncology, and inflammatory diseases [1] Group 2 - The core product of Zhengxiang Pharmaceutical, Marcilosavir tablets, is an inhibitor targeting the influenza virus polymerase acidic protein (PA) endonuclease, which received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) in July 2025 for the treatment of adult influenza [4] - The company is expanding the indications of Marcilosavir to include adolescent patients and post-exposure prophylaxis [4] - Zhengxiang Pharmaceutical has developed a pipeline of six drug assets, including the commercialized Marcilosavir tablets, a clinical late-stage Marcilosavir suspension for pediatric influenza patients, and ZX-8177 for solid tumors in phase I clinical trials, along with ZX-12042B for human papillomavirus (HPV) infection currently in the IND application stage [4] - Additionally, the company has two clinical candidates for herpes simplex virus (HSV) infections and autoimmune diseases in preclinical stages [4]